Grant: Doctoral Research Award: Canada Graduate Scholarships
Université de Montréal
$120,000.00
Targeting the SMARCD1-p53 Axis in Pre-B Acute Lymphoblastic Leukemia
FY 2024-25
Summary
B-cell acute lymphoblastic leukemia (B-ALL) is a blood cancer marked by the uncontrolled and abnormal proliferation of malignant B-cells. It remains the most prevalent cancer in children, with treatment resistance and relapses posing significant challenges to patient care. Consequently, gaining insight into the mechanisms that mediate cancer cells survival is crucial for developing new therapies.
The subunit SMARCD1 of the chromatin remodeling complexes SWI/SNF, which are protein complexes that regulate gene expression, is essential for B-cell development. We have recently identified a critical interaction in B-ALL between SMARCD1 and the protein p53. Known as the 'guardian of the genome,' p53 is the most commonly mutated gene across all human cancers. However, some cancers retain a non-mutated p53 (WTp53) such as ALL. Our studies uncovered a dependence for SMARCD1 and WTp53 in B-ALL cells, and the loss of either protein leads to proliferation defect. Further genetic analyses revealed that SMARCD1 and WTp53 regulate common genes involved in metabolic processes and are present at overlapping regions of DNA.
Based on these results, we hypothesize that the interaction between SMARCD1 and WTp53 is essential for the metabolism of cancerous B-cells. Specifically, we want to 1) decipher the role of the SMARCD1-p53 axis in the regulation of metabolism. To do so, we will assess the changes in energy production when cells are SMARCD1- or p53-deficient. We also aim to 2) determine the therapeutic potential of targeting the SMARCD1-p53 interaction. To accomplish this, we will evaluate B-ALL progression when we block the interaction genetically or chemically.
To conclude, this project will help us better understand why certain cancers maintain a WTp53 and what molecular advantages these cancerous cells derive from this. Ultimately, it will also determine the therapeutic potential of blocking the interaction between SMARCD1 and p53 or perturbing the SMARCD1-p53 axis in B-ALL.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
518428
Name
Côté Laurence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting the SMARCD1-p53 Axis in Pre-B Acute Lymphoblastic Leukemia
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Chromatin Remodeling; Epigenetic; Hematologic Cancers; Leukemia; Metabolism; P53; Pioneer Transcription Factors; Smarcd1; Swi/Snf
Abstract
B-cell acute lymphoblastic leukemia (B-ALL) is a blood cancer marked by the uncontrolled and abnormal proliferation of malignant B-cells. It remains the most prevalent cancer in children, with treatment resistance and relapses posing significant challenges to patient care. Consequently, gaining insight into the mechanisms that mediate cancer cells survival is crucial for developing new therapies.
The subunit SMARCD1 of the chromatin remodeling complexes SWI/SNF, which are protein complexes that regulate gene expression, is essential for B-cell development. We have recently identified a critical interaction in B-ALL between SMARCD1 and the protein p53. Known as the 'guardian of the genome,' p53 is the most commonly mutated gene across all human cancers. However, some cancers retain a non-mutated p53 (WTp53) such as ALL. Our studies uncovered a dependence for SMARCD1 and WTp53 in B-ALL cells, and the loss of either protein leads to proliferation defect. Further genetic analyses revealed that SMARCD1 and WTp53 regulate common genes involved in metabolic processes and are present at overlapping regions of DNA.
Based on these results, we hypothesize that the interaction between SMARCD1 and WTp53 is essential for the metabolism of cancerous B-cells. Specifically, we want to 1) decipher the role of the SMARCD1-p53 axis in the regulation of metabolism. To do so, we will assess the changes in energy production when cells are SMARCD1- or p53-deficient. We also aim to 2) determine the therapeutic potential of targeting the SMARCD1-p53 interaction. To accomplish this, we will evaluate B-ALL progression when we block the interaction genetically or chemically.
To conclude, this project will help us better understand why certain cancers maintain a WTp53 and what molecular advantages these cancerous cells derive from this. Ultimately, it will also determine the therapeutic potential of blocking the interaction between SMARCD1 and p53 or perturbing the SMARCD1-p53 axis in B-ALL.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Côté, Laurence
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~